<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="127833">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02012075</url>
  </required_header>
  <id_info>
    <org_study_id>KWDLHF2012</org_study_id>
    <nct_id>NCT02012075</nct_id>
  </id_info>
  <brief_title>A Phase Ⅲ Study of Extended-Release Carvedilol Sulfate for the Treatment of Heart Failure</brief_title>
  <official_title>Efficacy and Safety Comparison of Extended-Release Carvedilol Sulfate and Sustained-release Metoprolol Succinate in Patients With Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of present study is to evaluate the efficacy and safety of Extended-Release
      Carvedilol Sulfate versus Sustained-release Metoprolol Succinate in Patients With Mild or
      Moderate Chronic Heart Failure.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <primary_completion_date type="Anticipated">February 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change From Baseline in left ventricular ejection fraction(LVEF) by ultrasound cardiogram</measure>
    <time_frame>Baseline and Week 36</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Left Ventricular End Systolic Volume Index</measure>
    <time_frame>Baseline and Week 36</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Left Ventricular End Diastolic Volume Index</measure>
    <time_frame>Baseline and Week 36</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Hospitalizations From Exacerbation of Heart Failure</measure>
    <time_frame>Baseline and Week 36</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Hospitalizations From  All Causes</measure>
    <time_frame>Baseline and Week 36</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Deaths From All Causes</measure>
    <time_frame>Baseline and Week 36</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in New York Heart Association（NYHA）classification</measure>
    <time_frame>Baseline and Week 36</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">316</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Extended-Release Carvedilol Sulfate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>18-72mg/d,po</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sustained-release Metoprolol Succinate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>11.875-190mg/d,po</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Extended-Release Carvedilol Sulfate</intervention_name>
    <arm_group_label>Extended-Release Carvedilol Sulfate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sustained-release Metoprolol Succinate</intervention_name>
    <arm_group_label>Sustained-release Metoprolol Succinate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or Females

          -  Aged from 18 to 75 years

          -  New York Heart Association(NYHA) classification Ⅱ-Ⅲ

          -  At screening, subject has an LVEF&lt;0.45

          -  Have received optimal therapy with an Angiotensin converting enzyme inhibitors or
             angiotensin receptor blocker  for 4 weeks before enrollment

          -  Subjects with symptoms of Stable heart failure do not need intravenous injection
             diuretics,cardiac inotropes or vasodilators

          -  Willing to provide written informed consent

        Exclusion Criteria:

          -  Current treatment on any Class I or III antiarrhythmic, except amiodarone or
             beta-blockers

          -  Current treatment on calcium antagonists except for long-acting dihydropyridine
             agents

          -  Have a history of acute coronary syndrome,cerebral apoplexy or transient ischemic
             attack with 3 months

          -  Have a history of  cardio-vascular surgery or other vessel operations with 3 months

          -  Have a history of sustained ventricular tachycardia or ventricular fibrillation with
             3 months

          -  Have a plan to receive coronary revascularization or heart transplantation

          -  Uncontrolled ventricular arrhythmias (not controlled with antiarrhythmic therapy or
             an implantable defibrillator)

          -  Subjects with uncorrected primary obstructive or severe regurgitative valvular
             disease，nondilated (restrictive) or hypertrophic cardiomyopathy

          -  Sitting systolic blood pressure≤90mmHg (based on an average of 3 readings)

          -  Current decompensated heart failure

          -  Second or third degree heart block，or sick sinus syndrome，a pacemaker is not placed

          -  Contraindication to vasodilators

          -  Have a history of cardiac resynchronization therapy or

          -  Have received cardioverter defibrillator or  pacemaker  with 1 month

          -  Resting heart rate&lt;50 beats per minute(based on the average of 3 readings)

          -  Elevated liver enzymes (alanine aminotransferase or aspartate aminotransferase levels
             greater than 3 times upper limit of normal)

          -  Serum creatinine levels greater than 2 times upper limit of normal

          -  Current clinical evidence of obstructive pulmonary disease (e.g., asthma or
             bronchitis) requiring inhaled or oral bronchodilator or steroid therapy

          -  History of drug sensitivity or allergic reaction to alpha or beta-blockers

          -  Contraindication or intolerance to beta-blockers

          -  Pregnant or lactating women and women planning to become pregnant

          -  Has any systemic disease, including cancer, with reduced life expectancy (&lt;12 months)

          -  Use of an investigational drug within 30 days of enrollment

          -  Participation in an investigational device trial within 30 days of enrollment

          -  Known drug or alcohol abuse 1 year prior to enrollment

          -  Has a history of psychological illness/condition that interferes with ability to
             understand or complete requirements of the study

          -  In the opinion of the investigator the subject is known to be noncompliant with
             prescribed medication regimen
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Changsheng Ma, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Anzhen Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Changsheng Ma, Professor</last_name>
    <phone>86-010-64456078</phone>
    <email>chshma@vip.sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Gansu Provincial Hospital</name>
      <address>
        <city>Lanzhou</city>
        <state>Gansu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tongji Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Second Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Third Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northern Jiangsu People's Hospital</name>
      <address>
        <city>Yangzhou</city>
        <state>Jiangsu</state>
        <zip>225001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shengjing Hospital of China Medical University</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110004</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of College of Medicine, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Taizhou Hospital</name>
      <address>
        <city>Taizhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beijing ANZHEN Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Changsheng Ma, Professor</last_name>
      <phone>86-010-64456078</phone>
      <email>chshma@vip.sina.com</email>
    </contact>
    <investigator>
      <last_name>Changsheng Ma, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>China-Japan Friendship Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beijing Tongren hospital affiliated to Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Xuan Wu Hospital affiliated to Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <zip>100053</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 10, 2013</lastchanged_date>
  <firstreceived_date>December 10, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Metoprolol</mesh_term>
    <mesh_term>Carvedilol</mesh_term>
    <mesh_term>Metoprolol succinate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
